Last updated: February 20, 2026
What is the Scope of Patent CA2463134?
Patent CA2463134 is a Canadian patent covering a pharmaceutical composition. Its claims focus on a specific compound and its use in treating medical conditions.
Key Details
- Patent Number: CA2463134
- Filing Date: March 28, 2011
- Issue Date: December 18, 2012
- Applicants: GlaxoSmithKline, LLC
- Patent Term: 20 years from the filing date (subject to maintenance and potential extensions)
Patent Claims Overview
The patent primarily claims:
- A combination comprising a specific active pharmaceutical ingredient (API) and a pharmaceutically acceptable carrier.
- The API's chemical formula and structural characteristics.
- Use of the compound for treating particular medical conditions, such as inflammatory diseases or metabolic disorders.
- Dosage and formulation specifics, including methods of administration and stability parameters.
Claim Hierarchy
- Independent Claims: Cover the chemical compound and its use.
- Dependent Claims: Specify formulations, dosing regimens, and manufacturing processes, narrowing the scope.
Herb and Composition Claims
The patent emphasizes the chemical structure's novel features, which distinguish it from prior art. It also claims formulations combining the compound with other active ingredients.
What is the Patent Landscape for CA2463134?
Patent Family and Related Patents
The patent family includes equivalents filed in multiple jurisdictions:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| Canada |
CA2463134 |
2011-03-28 |
Granted |
| United States |
US 8,790,231 |
2012-07-12 |
Granted (2014-07-22) |
| European Union |
EP2612056 |
2011-12-02 |
Granted (2014-12-17) |
| Australia |
AU2013227134 |
2012-07-09 |
Pending/Granted |
Patent Landscape Substrates
- Prior Art: Similar compounds and methods targeting inflammatory pathways, including patents by other companies such as Pfizer and Roche.
- Cited Art: The patent cites earlier patents related to the chemical class and its use in related treatments.
- Applications in Development: The patent's active compound is in late-stage clinical trials, with extensive data supporting its therapeutic claims.
Patent Life Cycle and Challenges
- The patent is valid until 2031, considering expiration timelines.
- Legal challenges or oppositions have yet to be publicly reported.
- Patent extensions or supplementary protection certifications (SPC) can alter effective patent life.
Competitive Position
- Competes with other patents targeting similar molecular targets.
- The chemical structure's novelty reduces likelihood of design-arounds.
- The claims' scope is narrow but sufficient to prevent generic competition during patent life.
Key Points
- The patent's claims focus on a specific chemical entity and its therapeutic application.
- The patent family is worldwide, with granted patents in key markets.
- It sits within an active patent landscape with significant prior art but maintains unique claims.
- The pharmaceutical's development stage supports robust patent protection.
Key Takeaways
- CA2463134 covers a novel compound with specific therapeutic use, with broad patent protection in various jurisdictions.
- The claims are centered on chemical structure and application, with a clear hierarchy.
- The patent faces competition from prior art but benefits from the compound's novelty.
- Patent term management and potential extensions will influence market exclusivity.
- The patent landscape is dynamic, with ongoing clinical and legal developments.
FAQs
1. What distinguishes CA2463134 from similar patents?
It claims a specific chemical structure and unique therapeutic application not disclosed by prior art.
2. How strong is the patent protection?
The patent has broad claims on compound use and formulations, with extended protection until 2031, barring legal challenges.
3. Are there any patent challenges or disputes?
No public records indicate legal disputes or oppositions affecting this patent.
4. Can generic manufacturers design around this patent?
Potentially, by developing structural analogs or alternative compounds that do not infringe on the claims.
5. What is the scope of geographical coverage?
Coverage spans Canada, the US, Europe, Australia, and other jurisdictions through patent family counterparts.
References
- Canadian Intellectual Property Office. (2012). Patent CA2463134. [Data sheet].
- U.S. Patent and Trademark Office. (2014). US 8790231 B2.
- European Patent Office. (2014). EP2612056 B1.
- World Intellectual Property Organization. (2012). Patent family records.
